Acacia Research Corp. Subsidiary Acquires Rights to Patents for Laparoscopic Surgery Technology
"As Acacia's licensing success grows, more companies are selecting us as their partner for the licensing of their patented technologies," commented Paul Ryan, Acacia Chairman and CEO. "Acacia is rapidly becoming the leader in technology licensing and we continue to grow our base of future revenues by adding new patent portfolios," concluded Mr. Ryan.
The patented technology relates to devices used by surgeons to help repair broken or damaged blood vessels or gastrointestinal organs. The devices can be used by cardiologists, gastrointestinal specialists, and other medical professionals.
ABOUT ACACIA RESEARCH CORPORATION
Acacia Research’s subsidiaries develop, acquire, and license patented technologies. Acacia Research’s subsidiaries control 92 patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries.
Information about Acacia Research is available at www.acaciatechnologies.com and www.acaciaresearch.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
Contact: Acacia Research Corporation Rob Stewart, Investor Relations, 949-480-8300 Fax: 949-480-8301
Source: Acacia Research Corporation